Nuvectis Pharma (NVCT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
Annual meeting scheduled for June 11, 2026, with voting open until June 10, 2026.
Shareholders can access proxy materials online or request paper/email copies by May 28, 2026.
Voting matters and shareholder proposals
Election of Ron Bentsur as director is up for shareholder vote.
Ratification of Kesselman & Kesselman (PwC member) as independent auditor for fiscal year ending December 31, 2026.
Other business may be transacted as properly brought before the meeting or any adjournment.
Audit committee and external auditor matters
Proposal to ratify Kesselman & Kesselman as the independent registered public accounting firm for 2026.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Nuvectis Pharma
- Advancing late-stage precision therapies for complement diseases and cancer with strong clinical data.NVCT
Corporate presentation - Q2 2026 net loss was $7.0M; $115M raised in July extends cash runway into 1H 2029.NVCTQ2 2026
- Late-stage NXP100 and NXP200 in-licensed, expanding pipeline in complement and oncology.NVCTStatus update
- Director election and auditor ratification approved; full results to be filed with SEC.NVCTAGM 2026
- NXP900 demonstrates potent, selective SRC inhibition and promising safety in early clinical trials.NVCTH.C. Wainwright 4th Annual BioConnect Investor Conference
- NXP900 shows promise in overcoming resistance in solid tumors and NSCLC with strong early data.NVCTCorporate presentation
- Q1 2026 net loss was $6.1M as NXP900 clinical progress drove higher R&D and G&A costs.NVCTQ1 2026
- Annual meeting to vote on director election and auditor ratification, with strong governance.NVCTProxy filing
- NXP900’s oral regimen targets resistance and unmet needs in NSCLC with a novel, well-tolerated approach.NVCTKOL Event